Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + weekly paclitaxel + anlotinib in platinum‑resistant recurrent ovarian cancer (Phase II, single‑arm)
ChiCTR2000035072Phase 2Recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Jul 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, paclitaxel and anlotinib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal adenocarcinoma (PPC), sponsored by The First Hospital of Jilin University. Primary endpoint: Progression-free survival (PFS). Started Jul 2021; status: recruiting.
02
Drugs
sintilimabpaclitaxelanlotinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal adenocarcinoma (PPC)
Beyond the preview
Go deeper on ChiCTR2000035072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035072.